Macrogenics (NASDAQ: MGNX) reported Q2 EPS of ($1.10), $1.02 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $32.83 million versus the consensus estimate of $59.14 million.

For earnings history and earnings-related data on Macrogenics (MGNX) click here.